Next Article in Journal
The Role of JAK2 Abnormalities in Hematologic Neoplasms
Previous Article in Journal
MicroRNAs: Tiny Players with a Big Role in the Pathogenesis of Leukemias and Lymphomas
Hematology Reviews (renamed as Hematology Reports here since 2010) is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Histone Deacetylase Inhibitors in Multiple Myeloma

Myeloma Research Center-Brussels, Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium
Department of Toxicology, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium
Author to whom correspondence should be addressed.
Hematol. Rev. 2009, 1(1), e9; (registering DOI)
Submission received: 9 February 2009 / Revised: 20 April 2009 / Accepted: 27 April 2009 / Published: 3 June 2009


Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.

Share and Cite

MDPI and ACS Style

Deleu, S.; Menu, E.; Van Valckenborgh, E.; Van Camp, B.; Fraczek, J.; Vande Broek, I.; Rogiers, V.; Vanderkerken, K. Histone Deacetylase Inhibitors in Multiple Myeloma. Hematol. Rev. 2009, 1, e9.

AMA Style

Deleu S, Menu E, Van Valckenborgh E, Van Camp B, Fraczek J, Vande Broek I, Rogiers V, Vanderkerken K. Histone Deacetylase Inhibitors in Multiple Myeloma. Hematology Reviews. 2009; 1(1):e9.

Chicago/Turabian Style

Deleu, Sarah, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, and Karin Vanderkerken. 2009. "Histone Deacetylase Inhibitors in Multiple Myeloma" Hematology Reviews 1, no. 1: e9.

Article Metrics

Back to TopTop